Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bucillamine - Revive Therapeutics

Next Previous
Drug Profile

Bucillamine - Revive Therapeutics

Alternative Names: REV-002; REV-004; REV-005

Latest Information Update: 19 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Revive Therapeutics
  • Class Antigouts; Antivirals; Cysteines; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Sulfhydryl compounds; Sulfur amino acids
  • Mechanism of Action Antioxidants; Chelating agents; Immunomodulators; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinuria; Ischaemia; COVID 2019 infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Cystinuria; Gout
  • Clinical Phase Unknown Chemically-induced disorders
  • Research Unspecified
  • No development reported Hepatolenticular degeneration

Most Recent Events

  • 12 May 2025 Revive Therapeutics plans a phase I trial for Chemically-induced disorders in Canada and USA in the second half of 2025
  • 11 Apr 2025 Revive Therapeutics plans a clinical trial for Solid tumours
  • 03 Feb 2025 Revive Therapeutics plans to submit phase II study protocol for the treatment of COVID-2019 infections by the end of Q1 of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top